Toad psychedelic points to biological target for antidepressants
Nature May 8, 2024 DOI: 10.1038/d41586-024-01296-x (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Keywords | Structural biology Chemical biology Drug discovery |
| Key points | Psychedelic compounds exert antidepressant effects in part by binding an under-appreciated target in the brain. |
Abstract
A hallucinogenic compound secreted by toads has served as a springboard for research into the therapeutic benefits of psychedelics. The findings suggest that these compounds exert antidepressant effects in part by binding an under-appreciated target in the brain. Research into a hallucinogenic compound secreted by a toad has cast light on the therapeutic effects of psychedelics.
Citations in the library
Cites 4
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine November 3, 2022
- Structural Features for Functional Selectivity at Serotonin Receptors Science March 21, 2013
- The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats. Psychopharmacology December 1, 2006
- The Varieties of the Psychedelic Experience: A Preliminary Study of the Association Between the Reported Subjective Effects and the Binding Affinity Profiles of Substituted Phenethylamines and Tryptamines Frontiers in Integrative Neuroscience November 1, 2018